Elastatherapy is a technology that has the potential to reverse ageing process and enable skin regeneration. The technology uses human protein Elastin to naturally repair and augment skin, a fine innovation for overcoming surgical excision of burns and scar tissue.

Australian company Elastagen, which was founded in 2005, pioneered the scientific understanding of elastin and the "elastagenesis" process, which is the formation of the elastic fibres found in the skin and other elastic tissues, such as blood vessels, lungs and elastic ligaments. The company is also capable of scalable commercial GMP-compliant manufacturing of full length recombinant human elastin.

The company received seed funding from ATP Innovations and also received an exclusive licence to the Elastin technology from the University of Sydney, Australia, which enabled it to complete proof-of-concept formulation and production activities. The commercially and clinically focussed phase of the company started in August 2008 following a Series A financing from leading Australian investors GBS Ventures and Brandon Capital Partners along with ATP Innovations.

Founding scientist Professor Anthony Weiss is leading head of Elastin Laboratory at University of Sydney and has been researching on elastin since early 1990s. Prof Weiss is internationally recognised as a scientific leader in the field and has pioneered technologies for the production of recombinant human elastin; its formulation into a range of biomaterials; and its application in diverse clinical areas, such as repair of blood vessels through to anti-ageing skin products. Both clinicians and established companies in the medical and cosmetic dermatology arenas have taken interest in elastin technology and its applications.

"Elastin offers a new generation of treatment in anti-ageing therapy, after Hyaluronic Acid (HA) and Botulinum toxin type A, which are now central tools in cosmetic dermatology.